These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 35503478)

  • 41. A PIAS1 Protective Variant S510G Delays polyQ Disease Onset by Modifying Protein Homeostasis.
    Lee YH; Tsai YS; Chang CC; Ho CC; Shih HM; Chen HM; Lai HL; Lee CW; Lee YC; Liao YC; Yang UC; Cheng TH; Chern Y; Soong BW
    Mov Disord; 2022 Apr; 37(4):767-777. PubMed ID: 34951052
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Discovery of Therapeutic Approaches for Polyglutamine Diseases: A Summary of Recent Efforts.
    Esteves S; Duarte-Silva S; Maciel P
    Med Res Rev; 2017 Jul; 37(4):860-906. PubMed ID: 27870126
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Functional genomics approaches to neurodegenerative diseases.
    Rubinsztein DC
    Mamm Genome; 2008 Sep; 19(9):587-90. PubMed ID: 18665420
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Growth assays to assess polyglutamine toxicity in yeast.
    Duennwald ML
    J Vis Exp; 2012 Mar; (61):e3461. PubMed ID: 22415521
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Peptide-based therapeutic approaches for treatment of the polyglutamine diseases.
    Takeuchi T; Popiel HA; Futaki S; Wada K; Nagai Y
    Curr Med Chem; 2014; 21(23):2575-82. PubMed ID: 24533807
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Identification of ter94, Drosophila VCP, as a modulator of polyglutamine-induced neurodegeneration.
    Higashiyama H; Hirose F; Yamaguchi M; Inoue YH; Fujikake N; Matsukage A; Kakizuka A
    Cell Death Differ; 2002 Mar; 9(3):264-73. PubMed ID: 11859409
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Coiled-coil structure-dependent interactions between polyQ proteins and Foxo lead to dendrite pathology and behavioral defects.
    Kwon MJ; Han MH; Bagley JA; Hyeon DY; Ko BS; Lee YM; Cha IJ; Kim SY; Kim DY; Kim HM; Hwang D; Lee SB; Jan YN
    Proc Natl Acad Sci U S A; 2018 Nov; 115(45):E10748-E10757. PubMed ID: 30348793
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Correlation of inter-locus polyglutamine toxicity with CAG•CTG triplet repeat expandability and flanking genomic DNA GC content.
    Nestor CE; Monckton DG
    PLoS One; 2011; 6(12):e28260. PubMed ID: 22163004
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Protein Aggregation Inhibitors as Disease-Modifying Therapies for Polyglutamine Diseases.
    Minakawa EN; Nagai Y
    Front Neurosci; 2021; 15():621996. PubMed ID: 33642983
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In vitro aggregating β-lactamase-polyQ chimeras do not induce toxic effects in an in vivo Caenorhabditis elegans model.
    Van Assche R; Borghgraef C; Vaneyck J; Dumoulin M; Schoofs L; Temmerman L
    J Negat Results Biomed; 2017 Aug; 16(1):14. PubMed ID: 28830560
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Large-scale RNA interference screening in mammalian cells identifies novel regulators of mutant huntingtin aggregation.
    Yamanaka T; Wong HK; Tosaki A; Bauer PO; Wada K; Kurosawa M; Shimogori T; Hattori N; Nukina N
    PLoS One; 2014; 9(4):e93891. PubMed ID: 24705917
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Polyglutamine tracts regulate beclin 1-dependent autophagy.
    Ashkenazi A; Bento CF; Ricketts T; Vicinanza M; Siddiqi F; Pavel M; Squitieri F; Hardenberg MC; Imarisio S; Menzies FM; Rubinsztein DC
    Nature; 2017 May; 545(7652):108-111. PubMed ID: 28445460
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Huntington's disease induced cardiac amyloidosis is reversed by modulating protein folding and oxidative stress pathways in the Drosophila heart.
    Melkani GC; Trujillo AS; Ramos R; Bodmer R; Bernstein SI; Ocorr K
    PLoS Genet; 2013; 9(12):e1004024. PubMed ID: 24367279
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Molecular chaperones as modulators of polyglutamine protein aggregation and toxicity.
    Sakahira H; Breuer P; Hayer-Hartl MK; Hartl FU
    Proc Natl Acad Sci U S A; 2002 Dec; 99 Suppl 4(Suppl 4):16412-8. PubMed ID: 12189209
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Towards the treatment of polyglutamine diseases: the modulatory role of protein context.
    Robertson AL; Bottomley SP
    Curr Med Chem; 2010; 17(27):3058-68. PubMed ID: 20629626
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Studying polyglutamine diseases in Drosophila.
    Xu Z; Tito AJ; Rui YN; Zhang S
    Exp Neurol; 2015 Dec; 274(Pt A):25-41. PubMed ID: 26257024
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Huntington toxicity in yeast model depends on polyglutamine aggregation mediated by a prion-like protein Rnq1.
    Meriin AB; Zhang X; He X; Newnam GP; Chernoff YO; Sherman MY
    J Cell Biol; 2002 Jun; 157(6):997-1004. PubMed ID: 12058016
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Increased aggregation of polyleucine compared with that of polyglutamine in dentatorubral-pallidoluysian atrophy protein.
    Suzuki Y; Jin C; Yazawa I
    Neurosci Lett; 2013 Sep; 552():156-61. PubMed ID: 23933208
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A huntingtin peptide inhibits polyQ-huntingtin associated defects.
    Arribat Y; Bonneaud N; Talmat-Amar Y; Layalle S; Parmentier ML; Maschat F
    PLoS One; 2013; 8(7):e68775. PubMed ID: 23861941
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.